Press release
Malignant Ascites Therapeutics Market Size in the 7MM was ~ USD 1990 Million in 2020, is expected to grow by 2034, and estimated DelveInsight
Discover Key Insights into the Malignant Ascites Market with DelveInsight's In-Depth Report @ [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Malignant Ascites Market Report
* Among the 7MM, the United States accounted for the highest incident cases of Malignant ascites in 2020, with around 350,000 cases; these cases are expected to increase during the forecast period.
* Among all the associated cancers, the highest incident cases were reported in Breast Cancer. In 2020 the total incident cases of Breast Cancer were 640,000.
* In 2020, the total patient pool of Malignant Ascites were 390,000 in the EU4 and the UK.
* The leading Malignant Ascites Companies such as Clover Biopharmaceuticals, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Jiangsu Simcere Pharmaceutical, Neovii Biotech, Sanofi , and others
* Promising Malignant Ascites Therapies such as SCB-313, M701, catumaxomab, Endostar, Catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP Registered ), and others
Navigate the complexities of the Malignant Ascites Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Malignant Ascites Market Forecast. Click here to get more insights @ Malignant Ascites Treatment Market [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Malignant Ascites Epidemiology Segmentation in the 7MM
* Total Incident Cases of Ascites in Selected Indications (Ovarian, Colorectal, Gastric, and Others) in the 7MM
* Incident Cases of Malignant Ascites in Selected Indications in the 7MM
* Total Treated Cases of Malignant Ascites in the 7MM
Download the report to understand which factors are driving Malignant Ascites epidemiology trends @ Malignant Ascites Prevalence [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Malignant ascites Emerging Drugs Profile
* Catumaxomab: Lindis Biotech
Catumaxomab is a bispecific trifunctional antibody that binds directly to the tumor cell with one of its binding sites. It activates two essential components of the immune system with the other binding sites: T cells and macrophages (scavenger cells). The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells. The EpCAM marker is present on almost all carcinomas and is, therefore, a promising approach for targeted cancer treatment. As per company pipeline, catumaxomab is in the preregistration stage of development for the treatment of Malignant ascites.
* M 701: Wuhan YZY Biopharma
M701 is a new biological Class I drug that targets both EpCAM and CD3 being developed by YBODY Biotech through its independently patented asymmetric bispecific antibody YBODY Registered platform. The drug is mainly used for the treatment of malignant ascites (MA) and malignant pleural effusion (MPE) derived from EpCAM-positive cancer.M701 dual-antibody targets the EpCAM antigen on one end. At the same time, the CD3 antibody on the other end can bridge T cells and activate T cells to kill EpCAM-positive tumor cells. Currently, M701 is in the Phase II stage of development for the treatment of malignant ascites.
Malignant Ascites Drugs Market Insights
Antibody-dependent cell cytotoxicity
Antibody-Dependent Cellular Cytotoxicity (ADCC) is a crucial mechanism of the immune system involving the targeting and destruction of pathogenic cells by effector cells, particularly natural killer (NK) cells. ADCC is a process where specific antibodies bind to pathogens, marking them for destruction by NK cells through the injection of cytotoxic factors, leading to cell lysis. Antibodies recognize and bind to target cells, which are then attacked and destroyed by effector cells like NK cells. This process plays a vital role in immune responses against pathogens and cancer cells.
Get In-Depth Knowledge on Malignant Ascites Market Trends and Forecasts with DelveInsight @ Malignant Ascites Treatment Market [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Malignant Ascites Therapies and Companies
* SCB-313: Clover Biopharmaceuticals
* M701: Wuhan YZY Biopharma Co., Ltd.
* catumaxomab: Neovii Biotech
* Endostar: Jiangsu Simcere Pharmaceutical
* Catumaxomab: Neovii Biotech
* aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP Registered ): Sanofi
Scope of the Malignant Ascites Market Report
* Study Period: 2020-2034
* Coverage: 7MM
* Malignant Ascites Companies: Clover Biopharmaceuticals, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Jiangsu Simcere Pharmaceutical, Neovii Biotech, Sanofi, and others
* Malignant Ascites Therapies: SCB-313, M701, catumaxomab, Endostar, Catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP Registered ), and others
* Malignant Ascites Therapeutic Assessment: Malignant Ascites current marketed and Malignant Ascites emerging therapies
* Malignant Ascites Market Dynamics: Malignant Ascites market drivers and Malignant Ascites market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Malignant Ascites Unmet Needs, KOL's views, Analyst's views, Malignant Ascites Market Access and Reimbursement
Gain a strategic edge in the Malignant Ascites Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Malignant Ascites Market Forecast. Click here to lead in advancements @ Malignant Ascites Clinical Trials Assessment [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Malignant Ascites Market Report Introduction
2. Executive Summary for Malignant Ascites
3. SWOT analysis of Malignant Ascites
4. Malignant Ascites Patient Share (%) Overview at a Glance
5. Malignant Ascites Market Overview at a Glance
6. Malignant Ascites Disease Background and Overview
7. Malignant Ascites Epidemiology and Patient Population
8. Country-Specific Patient Population of Malignant Ascites
9. Malignant Ascites Current Treatment and Medical Practices
10. Malignant Ascites Unmet Needs
11. Malignant Ascites Emerging Therapies
12. Malignant Ascites Market Outlook
13. Country-Wise Malignant Ascites Market Analysis (2020-2034)
14. Malignant Ascites Market Access and Reimbursement of Therapies
15. Malignant Ascites Market Drivers
16. Malignant Ascites Market Barriers
17. Malignant Ascites Appendix
18. Malignant Ascites Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=malignant-ascites-therapeutics-market-size-in-the-7mm-was-usd-1990-million-in-2020-is-expected-to-grow-by-2034-and-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Ascites Therapeutics Market Size in the 7MM was ~ USD 1990 Million in 2020, is expected to grow by 2034, and estimated DelveInsight here
News-ID: 3796162 • Views: …
More Releases from ABNewswire
Schneider Electric Launches Veteran Hiring Initiative to Build Mission-Ready Wor …
Schneider Electric, a global energy technology leader, today announced a new initiative to recruit and train U.S. military veterans for careers in its Services business. The effort will create pathways for up to 400 technicians, including veterans, to join Schneider Electric's workforce in customer-facing service representative roles supporting data centers, energy systems, and other mission-critical facilities.
Demand for skilled technicians is at an all-time high as industries that power the global…
Verde Market Continues to Grow in the Heart of Brooklyn Expanding Departments an …
About Verde Market: Verde Market is a locally owned Brooklyn neighborhood grocery store offering fresh produce, organic foods, international products, and household essentials. Located in the heart of Prospect Heights, Verde Market is committed to sustainability, local sourcing, and supporting the vibrant Brooklyn community.
Brooklyn, NY - November 10, 2025 - Verde Market, located at 646 Dean Street, Brooklyn, NY 11238, continues to strengthen its roots as one of Brooklyn's favorite…
Report: How to Fix the Hidden Security Risks of Vibe Coding - and Why Platforms …
AI-generated code is fast, but often dangerously insecure. A new report published by the Finance Herald Highlights why vibe-coded apps built with tools like Replit, Cursor, Lovable, and Bolt are vulnerable, and how freelancers on platforms like Fiverr have become the go-to solution enabling builders to audit, patch, and secure your AI-built product before launch.
Key Takeaways
* AI-generated code is fast but fragile. Vibe coding tools such as Cursor, Lovable, Bolt,…
MoneyDoll: Detroit's New Powerhouse Blending Pop, R&B, and Hip-Hop With Soul and …
Rising star MoneyDoll is shaking up the music world with her fearless fusion of Pop, R&B, and Hip-Hop, combining the soulful heart of Detroit with the confidence of a modern global artist. Her breakout single "Cookies", available now on all major platforms, introduces a sound that's as catchy as it is commanding - smooth vocals, bold lyricism, and undeniable charisma.
Image: https://www.abnewswire.com/upload/2025/11/b227c2b8aa6d6c2ab59677d0cafbc0a3.jpg
Carrying the Legacy - and Redefining It
Born into musical royalty…
More Releases for Malignant
Malignant Mesothelioma Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Malignant Mesothelioma Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.
Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.
Report Highlights
Publisher's Pharmaceutical…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
